Diagnostics; making a difference

Member Press Releases

Current Articles | Categories | Search | Syndication

05 February 2015  Joanne Hunter
NEW £20 BLOOD TEST A BREAKTHROUGH IN THE DIAGNOSIS OF BOWEL CANCER
By Joanne Hunter @ 09:02 :: 237 Views




·         New blood test will spot bowel cancer at earliest stage

·         Simple check will ID cancer missed by existing screening

·         No need for ‘unpleasant’ faecal screen

·         1-in-20 people in UK will develop bowel cancer

 

British and Irish scientists are developing a new £20 blood test for bowel cancer, which could save thousands of lives by spotting the disease at the earliest possible opportunity. The simple check will pick up on antibodies in the blood, produced as the body reacts to the onset of bowel cancer.

Read More

03 February 2015  Joanne Hunter
Proteome Sciences extends its reach through collaboration with MedBiomix Partners
By Joanne Hunter @ 09:18 :: 146 Views

Cobham, Surrey; 3rd Feb 2015. MedBiomix Partners SAS and Proteome Sciences Ltd are proud to announce they enter into a collaborative network alliance, whose goal is to provide healthcare professionals with advanced data-driven solutions to integrate and make better use of protein expression data that will significantly improve the life and disease conditions of their patients.

Read More

16 January 2015  Rebecca Bellars
UroSens Receives £2 Million Investment to Commercialise Urine-Based Diagnostic Test for Bladder and Prostate Cancer
By Rebecca Bellars @ 12:05 :: 251 Views



Cambridge and Sunderland, UK, 12 January 2015:
UroSens Ltd, a diagnostic company developing novel, non-invasive urine tests for the detection of prostate and bladder cancer, has announced it has received £2 million ($3.02 million) investment. The funding round was led by Longwall Venture Partners, with participation from shareholders including Northstar Ventures, Esperante BV, Cambridge Capital Group and other existing shareholders. 

Read More

15 January 2015  Joanne Hunter
EKF highlighting heat and humidity compatible POC hemoglobin analyzer at Arab Health 2015
By Joanne Hunter @ 16:13 :: 207 Views

Cardiff, UK – 15th January 2015 – EKF Diagnostics, the global diagnostics company, announces that it will be highlighting the robustness of its new DiaSpect Tm point of care (POC) hemoglobin analyzer at Arab Health 2015, 26-29th January, Dubai, UAE. Also on Stand Z1G30, EKF will be discussing its new liquid-stable assay* for early sepsis detection, as well as previewing SensPoint, a new hand-held lactate analyzer with built-in connectivity functions to hospital or laboratory information systems.

Read More

15 January 2015  Joanne Hunter
Randox puts British Biotechnology on World Map with New Randox Science Park
By Joanne Hunter @ 08:48 :: 216 Views


  • £161m investment including £29m capital project and creation of 540 jobs
  • Next generation medical diagnostics manufacturing facility
  • World leading R&D into conditions such as cancer, stroke, heart disease, neurodegenerative disorders, sepsis, STIs, aspirin resistance and respiratory infections

“This investment and expansion reinforces our dedication to improving health worldwide…”

Read More

14 January 2015  Joanne Hunter
VersaCell X3: Enhanced workflow within a small footprint
By Joanne Hunter @ 09:16 :: 215 Views



Siemens Healthcare Diagnostics has recently unveiled its latest advancements in compact robotic laboratory automation solutions. The VersaCell® X3 consolidates sample management for chemistry and immunoassay testing. The system assists laboratories to achieve some of the workflow benefits of automation without the space or budget considerations associated with a track-based solution. Siemens has already completed the first UK installation. 

Read More

12 December 2014  Joanne Hunter
Abbott 's Pioneering, Infectious Disease Testing Platform, IRIDICA, Now Available in Europe
By Joanne Hunter @ 08:50 :: 434 Views


- IRIDICA has the potential to change how pathogens that cause serious infections, such as sepsis and pneumonia, are detected and identified

- May provide doctors with information needed to start treating those who are critically ill with appropriate therapies sooner

- May help reduce the use of broad-spectrum antibiotics, a leading cause of antibiotic resistance

Read More

09 December 2014  Joanne Hunter
Mast Group Ltd wins Outstanding Achievement accolade at the Medilink Awards
By Joanne Hunter @ 08:42 :: 353 Views

Bootle-based Mast Group has won the Medical Engineers Outstanding Achievement Award at the Medilink North West Awards.

Read More

05 December 2014  Joanne Hunter
Hologic Enters the Viral Load Market with CE Mark Certification for the Aptima HIV-1 Viral Load Test
By Joanne Hunter @ 10:18 :: 396 Views

The new assay is certified for both diagnosis and viral load monitoring on the Panther system

Bedford, Mass., Dec. 1, 2014 -- Hologic, Inc. (NASDAQ: HOLX), today announced CE mark certification for its new Aptima HIV-1 Quant Dx assay for use on the Company’s Panther system. The Aptima HIV-1 Quant Dx assay, employing Hologic proprietary real-time transcription-mediated amplification (Real-time TMA) technology, is the first HIV viral load assay with a dual claim for both diagnosis and treatment monitoring. This milestone marks Hologic’s entry into the viral load market.

Read More

28 November 2014  Joanne Hunter
SYSQUANT® – UPDATE/CONTRACT AWARDS
By Joanne Hunter @ 13:52 :: 403 Views

28 November, 2014: The board is pleased to announce that the further assessment of an additional 20 cases of pancreatic cancer using SysQuant® has recently been completed. The results validate the findings from the first 12 cases that were published earlier this year in PLOS ONE. As well as potential new drug targets, a key outcome of this study is a set of new biomarkers predicting the likelihood and timescale of tumour recurrence after surgery and the ability to match patients to individual drug treatments. Proteome has already filed patent applications around these markers.

Read More

Previous Page | Next Page